📰 Priority Review News
Page 96 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
August 22, 2022
The best uncensored news, information, and analysis.
August 22, 2022
The FDA has accepted for Priority Review the BLA for beremagene geperpavec for the treatment of dystrophic epidermolysis bullosa.
August 19, 2022
The FDA has accepted the filing of a biologic license application (BLA) for B-VEC, a treatment of Krystal Biotech Inc. for patients with DEB.
August 19, 2022
Novavax vaccine booster update; over-the-counter hearing aids; Priority Review for a castration-resistant prostate cancer combination Tx.
August 17, 2022
New therapy is aimed at patients with metastatic castration-resistant prostate cancer - News - PharmaTimes
August 17, 2022
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to...
August 17, 2022
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment...
August 17, 2022
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment...
August 16, 2022
Investegate announcements from AstraZeneca PLC, Lynparza granted FDA priority review for PROpel
August 16, 2022
AstraZeneca's Lynparza granted FDA priority review for PROpel